Search
News & Events
Keelan has ‘survived and thrived’, thanks to researchTen-year-old Keelan Mullins is known to his mum Clare Hindle as her ‘miracle baby’. Keelan was born in March 2013 at 26 weeks’ gestation and weighing just 1096 grams.
The Wal-yan Respiratory Research Centre conducts research into a wide range of childhood respiratory disease areas.
Research
The role of exome sequencing in childhood interstitial or diffuse lung diseaseChildren’s interstitial and diffuse lung disease (chILD) is a complex heterogeneous group of lung disorders. Gene panel approaches have a reported diagnostic yield of ~ 12%. No data currently exist using trio exome sequencing as the standard diagnostic modality.
Research
Primary Nasal Epithelial Cells as a Surrogate Cell Culture Model for Type-II Alveolar Cells to Study ABCA-3 DeficiencyATP Binding Cassette Subfamily A Member 3 (ABCA-3) is a lipid transporter protein highly expressed in type-II alveolar (AT-II) cells. Mutations in ABCA3 can result in severe respiratory disease in infants and children. To study ABCA-3 deficiency in vitro, primary AT-II cells would be the cell culture of choice although sample accessibility is limited. Our aim was to investigate the suitability of primary nasal epithelial cells, as a surrogate culture model for AT-II cells, to study ABCA-3 deficiency.
Research
Pre-Post Intervention to Strengthen and Sustain the Paediatric ESCALATION System (The SPECS): Study ProtocolPromptly recognising changes in an acutely unwell child’s condition is fundamental to prevent tragic outcomes. Western Australian (WA) healthcare facilities used inconsistent and varied paediatric early warning systems. To improve care consistency, a standardised ESCALATION system, inclusive of family involvement and sepsis recognition, was developed.
Research
Considerations for Causal Inference StudiesRachel Foong BSc (hons), PhD, MBiostat Honorary Research Associate 08 6319 1626 Rachel.Foong@thekids.org.au Senior Research Fellow Dr Foong is an
Research
Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trialWe tested if disrupting iron utilisation by P. aeruginosa by adding the Tris-buffered chelating agent CaEDTA to nebulised tobramycin would enhance bacterial clearance and improve lung function in CF patients.
News & Events
Perth campaign aims to raise awareness of dangers of a chronic wet cough in Aboriginal childrenAn intensive health promotion campaign which aims to raise awareness of the dangers of a chronic wet cough in Aboriginal children launched this month in Perth.
News & Events
New drug offers hope for people living with cystic fibrosisA promising new treatment pioneered in Western Australia for people with cystic fibrosis has commenced testing in a clinical trial in the United States and Australia.
News & Events
Patients with antibiotic-resistant lung infections to receive promising phage therapy treatment as part of new trial led by The Kids Research Institute Australia Researcher Anthony KicicPatients with lung infections that are not responding to antibiotics will be treated with phage therapy as part of a translational trial program to be undertaken by world-recognised experts in this field.